Charles River Laboratories International (NYSE:CRL) Issues FY25 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share guidance of $9.10-$9.60 for the period, compared to the consensus earnings per share estimate of $9.60. The company issued revenue guidance of $3.77-$3.87 billion, compared to the consensus revenue estimate of $3.87 billion. Charles River Laboratories International also updated its FY 2025 guidance to 9.100-9.600 EPS.

Analyst Ratings Changes

Several brokerages recently issued reports on CRL. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a report on Monday, November 18th. TD Cowen raised their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a report on Monday, November 11th. Barclays cut their price target on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a report on Tuesday. Morgan Stanley cut their price target on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. Finally, The Goldman Sachs Group cut their price target on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $196.43.

Charles River Laboratories International Price Performance

Shares of CRL traded down $0.24 during midday trading on Thursday, reaching $164.77. The stock had a trading volume of 244,801 shares, compared to its average volume of 1,004,037. Charles River Laboratories International has a 52 week low of $150.79 and a 52 week high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The firm’s 50 day moving average price is $174.02 and its 200-day moving average price is $188.99. The company has a market capitalization of $8.43 billion, a P/E ratio of 20.60, a P/E/G ratio of 6.01 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the previous year, the business earned $2.46 EPS. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. On average, analysts forecast that Charles River Laboratories International will post 10.16 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).